» Articles » PMID: 38023436

Real-world Survival After Colorectal Surgery for Malignancy in Korean Patients with Chronic Kidney Disease: an Analysis of Korean Healthcare Big Data, 2002-2019

Overview
Specialty General Surgery
Date 2023 Nov 29
PMID 38023436
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Globally, chronic kidney disease (CKD) is common and has been associated with an increased risk of colorectal cancer (CRC). There is a dearth of literature on the real-world morbidity and mortality associated with CKD comorbid with CRC. This study was performed to evaluate real-world survival outcomes of colorectal malignancy in Korean CKD patients.

Methods: The National Health Insurance Service of Korea provided data on patients who underwent surgical resection among patients diagnosed with CRC from 2002 to 2019.

Results: A total of 219,550 patients were included: 6,181 patients with underlying CKD and 213,369 patients without it. Each morbidity was significantly higher in the CKD-CRC group, and the postoperative mortality rates for the 30-day (3.11% 1.78%, P < 0.001), 60-day (5.95% 3.83%, P < 0.001), and 90-day mortality rate (8.12% 5.32%, P < 0.001) were significantly higher in the CKD group. The median survival time (MST, year) was significantly lower in the CKD-CRC group (5.63; interquartile range [IQR], 5.26-5.91) than in the non-CKD-CRC group (8.71; IQR, 8.37-8.93). MST was significantly lower among CKD patients who received chemotherapy after adjustment by multivariate analysis (adjusted hazard ratio [HR], 1.43; 95% confidence interval [CI], 1.37-1.49; P < 0.001]). Subgroup analysis showed that in the CKD-CRC group, MST was lower in patients who received dialysis than in those who did not, even after multivariate analysis (adjusted HR, 2.38; 95% CI, 2.20-2.58; P < 0.001).

Conclusion: Prevention of CKD-to-end-stage renal disease progression should be adopted as a strategy to increase postoperative survival, along with active surveillance and cancer treatment.

Citing Articles

The Role of Indoxyl Sulfate in Exacerbating Colorectal Cancer During Chronic Kidney Disease Progression: Insights into the Akt/β-Catenin/c-Myc and AhR/c-Myc Pathways in HCT-116 Colorectal Cancer Cells.

Ichisaka Y, Takei C, Naito K, Higa M, Yano S, Niwa T Toxins (Basel). 2025; 17(1).

PMID: 39852970 PMC: 11769072. DOI: 10.3390/toxins17010017.

References
1.
Shebl F, Warren J, Eggers P, Engels E . Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study. BMC Nephrol. 2012; 13:65. PMC: 3441292. DOI: 10.1186/1471-2369-13-65. View

2.
Huang C, Huang L, Chen C, Wang W, Yang S . Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients with chronic kidney disease. Am J Surg. 2020; 221(1):162-167. DOI: 10.1016/j.amjsurg.2020.07.015. View

3.
Swartling O, Rydell H, Stendahl M, Segelmark M, Trolle Lagerros Y, Evans M . CKD Progression and Mortality Among Men and Women: A Nationwide Study in Sweden. Am J Kidney Dis. 2021; 78(2):190-199.e1. DOI: 10.1053/j.ajkd.2020.11.026. View

4.
Chen D, Davis B, Simpson L, Cushman W, Cutler J, Dobre M . Association between chronic kidney disease and cancer mortality: A report from the ALLHAT. Clin Nephrol. 2016; 87 (2017)(1):11-20. DOI: 10.5414/CN108949. View

5.
Drolet S, MacLean A, Myers R, Shaheen A, Dixon E, Buie W . Morbidity and mortality following colorectal surgery in patients with end-stage renal failure: a population-based study. Dis Colon Rectum. 2010; 53(11):1508-16. DOI: 10.1007/DCR.0b013e3181e8fc8e. View